PRAME family member 13 (PRAMEF13)

PRAME family member 13 (PRAMEF13) is a putative member of the PRAME (Preferentially Expressed Antigen in Melanoma) gene family, which encodes leucine-rich repeat (LRR) proteins. These proteins offer a versatile framework for protein–protein interactions and are involved across the PRAME family in biological processes such as reproduction, cell differentiation, and potentially repression of retinoic acid receptor signaling, immune regulation, and cancer[1][5]. However, as of current scientific knowledge, there are no published studies specifically characterizing PRAMEF13’s function, biological activity, or disease associations in humans. The gene is annotated in databases such as Ensembl (ENSG00000279169) and located on chromosome 1 (positions 13,196,188–13,201,409, GRCh38), with reported transcript evidence but no functional annotation[2][4]. While some PRAME family members have established roles in cancer and immunology, there is a lack of direct experimental evidence linking PRAMEF13 to any therapeutic targeting, clinical biomarker use, molecular mechanism, or specific safety concerns. Key points regarding PRAMEF13: - It is correctly annotated as a gene but is not currently recognized as a validated therapeutic target, nor is there evidence for disease involvement or druggability[2][4]. - The target’s naming and sequence are accurate, but the lack of functional or disease association makes it unsuitable as a drug target at present. - Most PRAME-related research focuses on the canonical PRAME gene or close paralogs; PRAMEF13 remains uncharacterized. Therefore, the target is likely included on lists of PRAME family genes without evidence of functional relevance, and should not be considered an actionable or therapeutic target until further research emerges[4][2].

Other names

PRAME family member 13PRAMEF13PRAME family member-likeputative PRAME family member 13